Welcome to our dedicated page for The Oncology Institute SEC filings (Ticker: TOI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncology Institute filings document a public oncology services company with common stock and redeemable warrants listed on Nasdaq. Current reports furnish financial results, guidance updates, investor presentations, and Regulation FD materials tied to the company’s value-based community oncology model and specialty pharmacy operations.
Proxy and governance filings cover annual meeting matters, director elections, board composition, executive compensation, and stockholder voting procedures. The filing record also includes 8-K disclosures for director appointments and resignations, officer-related matters, and the registered security classes that define TOI’s public capital structure.
The Oncology Institute, Inc. has called a virtual annual stockholder meeting for June 17, 2026 at 11:00 a.m. Pacific Time, accessible via webcast at www.proxydocs.com/TOI. Stockholders of record as of April 24, 2026, representing 99,982,933 common shares, may vote.
Investors are being asked to elect eight directors, ratify BDO USA, P.C. as independent auditor for the year ending December 31, 2026, approve on an advisory basis executive compensation, and select the preferred frequency of future say-on-pay votes, with the Board recommending annual votes. The Board highlights a majority of independent directors, separated Chair and CEO roles, and standard board committees overseeing audit, compensation, governance and healthcare compliance. The proxy also details 2025 executive pay packages combining salary, performance-based cash bonuses tied to revenue, gross profit and Adjusted EBITDA, and time-vested equity awards.
Oncology Institute, Inc. filed a Form 4 for Chief Administrative Officer Kristin England that shows no reportable insider trades during the period covered. The filing lists zero purchases, zero sales, zero derivative exercises, and no gifts, tax withholdings, or restructuring-related transfers.
Oncology Institute, Inc. insider Jeffrey Langsam, the company’s Chief Clinical Officer, filed a Form 4 reporting his status as an officer but no transactions in company securities. The provided data show no purchases, sales, exercises, gifts, or other changes in his reported holdings.
Oncology Institute, Inc. director Mohit Kaushal reported open-market sales of 95,719 shares of Common Stock. He sold 57,286 shares on April 14, 2026 at a volume-weighted average price of $3.5017 per share and 38,433 shares on April 16, 2026 at a volume-weighted average price of $3.5005 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the reported sales, Kaushal directly holds 172,583 shares of Oncology Institute common stock.
Oncology Institute, Inc. ten percent owner Jorey Chernett reported an open-market purchase of common stock. On April 9, 2026, Chernett bought 20,000 shares at $3.10 per share. After this purchase, Chernett directly owned 10,499,358 common shares.
Langsam Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Clinical Officer, Jeffrey Langsam, received a grant of 70,270 shares of common stock in the form of restricted stock units. These RSUs were granted at no cash cost per share and increase his direct holdings to 127,650 shares after the award.
The footnote explains that one quarter of the RSUs will vest on the first anniversary of the Vesting Commencement Date, with the remaining units vesting in three equal annual installments on each of the next three anniversaries. All RSUs are subject to continued service with the company through the respective vesting dates.
England Kristin reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that Chief Administrative Officer Kristin England received a grant of 55,743 shares of common stock in the form of restricted stock units (RSUs) at no cash cost. Following this award, she directly holds 153,780 shares of the company’s common stock.
The RSUs vest over four years, with one quarter vesting on the first anniversary of the vesting commencement date and the remaining three quarters vesting in equal annual installments on each of the next three anniversaries, subject to her continued service with the company.
Podnos Yale reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Medical Officer, Yale Podnos, received a grant of 66,446 shares of common stock on March 27, 2026 at no cost as part of a restricted stock unit (RSU) award. According to the terms, one quarter of the RSUs vest on the first anniversary of the vesting commencement date, with the remaining portions vesting in three equal annual installments so that all units vest by the fourth anniversary, subject to continued service. The issuer also executed a sale of 16,173 shares at $3.07 per share to cover tax liabilities arising from the vesting of an RSU award on March 31, 2026, a mechanistic tax-related transaction rather than an open-market trade.